tbuckley/cabot-search huggingface dataset:
Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE)
Authors: Siew C Ng, Michael A Kamm, Yun Kit Yeoh, Paul K S Chan, Tao Zuo, Whitney Tang, Ajit Sood, Akira Andoh, Naoki Ohmiya, Yongjian Zhou, Choon Jin Ooi, Varocha Mahachai, Chun-Ying Wu, Faming Zhang, Kentaro Sugano, Francis K L Chan
Journal: Gut (2019)

Objective The underlying microbial basis, predictors of therapeutic outcome and active constituent(s) of faecal microbiota transplantation (FMT) mediating benefit remain unknown. An international panel of experts presented key elements that will shape forthcoming FMT research and practice. Design Systematic search was performed, FMT literature was critically appraised and a 1-day round-table discussion was conducted to derive expert consensus on key issues in FMT research. Results 16 experts convened and discussed five questions regarding (1) the role of donor and recipient microbial (bacteria, viruses, fungi) parameters in FMT; (2) methods to assess microbiota alterations; (3) concept of keystone species and microbial predictors of FMT, (4) influence of recipient profile and antibiotics pretreatment on FMT engraftment and maintenance and (5) new developments in FMT formulations and delivery. The panel considered that variable outcomes of FMT relate to compositional and functional differences in recipient’s microbiota, and likely donor-associated and recipient-associated physiological and genetic factors. Taxonomic composition of donor intestinal microbiota may influence the efficacy of FMT in recurrent Clostridioides difficile infections and UC. FMT not only alters bacteria composition but also establishes trans-kingdom equilibrium between gut fungi, viruses and bacteria to promote the recovery of microbial homeostasis. FMT is not a one size fits all and studies are required to identify microbial components that have specific effects in patients with different diseases. Conclusion FMT requires optimisation before their therapeutic promise can be evaluated for different diseases. This summary will guide future directions and priorities in advancement of the science and practice of FMT.
GNF-2, An Allosteric BCR-ABL Inhibitor, Identifies a Novel Myristoylation-Mediated Mechanism Regulating the Ability of BCR-ABL to Activate HCK and IGF-1 Signaling.
Authors: Ron Geyer, Teodora Zlateva, Asha Lakshmikuttyamma, David P. Sheridan, John F. DeCoteau
Journal: Blood (2009)
Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies Using a Non-ATG Containing Reduced Intensity Preparative Regimen
Authors: Fabiana Ostronoff, Filippo Milano, Ted Gooley, Jonathan Gutman, Peter A. McSweeney, Finn Petersen, Brenda M. Sandmaier, Rainer Storb, Colleen Delaney
Journal: Blood (2011)
Long Term Survival after ASCT for AML: Multivariate Analysis Shows Adverse Effect of Collecting and Infusing Larger Numbers of CD 34 Positive Cells.
Authors: Clarence B. Sarkodee-Adoo, Anthony S. Stein, Margaret R. O’Donnell, Ravi M. Bhatia, E. Bolotin, K. P. Chang, Mark Kirschbaum, Neil Kogut, Auayporn Nademanee, Pablo Parker, Vinod Pullarkat, David Snyder, Ricardo Spielberger, Marilyn L. Slovak, Joseph Alvarnas, Joy Fridey, Jeffrey Schriber, Eileen Smith, Andy Dagis, J. Land, J. Palmer, N. Vora, Stephen Forman
Journal: Blood (2005)
Cbfb-MYH11 Induces Expansion of a Lin-Kit+Sca1- Abnormal Progenitor Compartment that Predisposes Acute Myeloid Leukemia in Mice.
Authors: Ya-Huei Kuo, Susan Heilman, Amy Chen, Pu P. Liu, Rachel Gernstein, Scott Kogan, Lucio H. Castilla
Journal: Blood (2004)
Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response
Authors: Caner Saygin, Nikolaos Papadantonakis, Ryan D Cassaday, Michaela Liedtke, Katrina Fischer, Tamara J. Dunn, Bhumika Patel, Sean Hobson, Cassie Zimmerman, Jaime Lynn Fensterl, Ronald M. Sobecks, Matt Kalaycio, Mikkael A. Sekeres, Sudipto Mukherjee, Aaron T. Gerds, Betty K. Hamilton, Hetty E. Carraway, Anjali S. Advani
Journal: Blood (2016)
Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia
Authors: Sarah K Tasian, Yong Li, Feng Shen, Theresa Ryan, Tiffaney L Vincent, David T Teachey, Shannon L Maude, Richard C Harvey, I-Ming L Chen, Cheryl L Willman, Alexander E. Perl, Stephen P Hunger, Mignon L. Loh, Martin Carroll, Stephan A. Grupp
Journal: Blood (2015)
Genome-Wide Single-Nucleotide Polymorphism-Array Based Karyotyping Detects Clonal Aberrations Including Uniparental Disomy (UPD), Gain or Loss Which Were Unfavorable Prognostic Factor In Acute Myeloid Leukemia with Normal Karyotype.
Authors: Dong Hwan (Dennis) Kim, Jungwon Huh, Boram Han, Ha Yeon Lee, Jun Ho Yi, Jun Ho Jang, Kihyun Kim, Hyeoung Joon Kim, Yeo-Kyeoung Kim, Sang Kyun Sohn, Joon Ho Moon, Sung Hyun Kim, Chul Won Jung
Journal: Blood (2010)
Predictive Value of Red Cell Indices and High Performance Liquid Chromatography in the Diagnosis of Haemoglobinopathies: Interim Results of the National Neonatal Cord Blood Screening Programme.
Authors: Anil Pathare, Salam AlKindi, Ali AlMadhani, Shoaib AlZadjali, Hamood AlHaddabi, Qamariya AlAbri, S. Muralitharan, J. David Dennison, R. Krishnamoorthy
Journal: Blood (2006)
Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I
Authors: Richard A. Van Etten, Wayne W. Chan, Virginia M. Zaleskas, Christoph Walz, Peter Evangelista, Katherine Lazarides, Monica Betancur, Scott Wise, Peter A. Petillo, Daniel L. Flynn
Journal: Blood (2008)
Alloreactivity of Natural Killer Cell Clones Against Childhood Precursor-B Lymphoblastic Leukemia Cells Is Determined by Differential KIR Expression.
Authors: Tobias Feuchtinger, Matthias Pfeiffer, Alexander Pfaffle, Heiko-Manuel Telschik, Rupert Handgretinger, Dorothee Wernet, Michael Schumm, Ramin Lotfi, Peter Lang
Journal: Blood (2006)
Imatinib Combined with Chemotherapy and Allogeneic Stem Cell Transplantation Results In Long Time Survival In Patients with De Novo Ph+ AML
Authors: Jie Sun, Zhen Wang, Yi Luo, Yamin Tan, Jimin Shi, Jingsong He, Wanzhuo Xie, Xiujin Ye, Zhen Cai, Maofang Lin, He Huang
Journal: Blood (2010)
The Early Treatment Response of the Clinically Challenging Group of Childhood T-ALL without NOTCH1 Mutations Is Signified by a Specific mRNA Gene Profile.
Authors: Andreas Kulozik, Stephen Breit, Stefan Pfister, Shangyou Liu, Martin Stanulla, Martin Schrappe, Wolf-Dieter Ludwig, Ulrike Köhl, Arndt Borkhardt, Renate Kirschner-Schwabe, Martina U. Muckenthaler
Journal: Blood (2007)
Cholesteryl ester storage disease: endoscopic findings of an orphan disease
Authors: Pavel V. Pavlov, Andrey P. Kiryukhin, Alexander S. Tertychnyi
Journal: Endoscopy (2019)

A 23-year-old man with normal antenatal history was admitted to hospital because of right hypochondrial pain, periodic nausea, and fatigue. The patient reported an episode of idiopathic jaundice with moderate fever 5 years previously. He was a non-smoker who did not drink alcohol nor take oral or intravenous drugs. Evaluation for viral hepatitis was negative. His physical examination revealed a high body mass index (BMI) of 32.2 kg/m2, his liver was palpable 2 cm below the costal margin, but his spleen was nonpalpable. Laboratory test results showed a leukocytosis, as well as high levels of total bilirubin (29.2 µmol/L), conjugated bilirubin (7.7 µmol/L), AST (48 U/L), total cholesterol (7.58 mmol/L), triglycerides (1.82 mmol/L), LDL-C (5.29 mmol/L), and VLDL-C (0.83 mmol/L), but his HDL-C level was normal (0.67 mmol/L).
The Management of EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Meiqing Wu, Yu Zhang, Fen Huang, Hongsheng Zhou, Zhiping Fan, Guopan Yu, Xutao Guo, Xian Zhang, Ru Feng, Jing Sun, Qifa Liu
Journal: Blood (2012)
Impact of Treatment on IL-10, CTLA-4 and PD-L1 Gene Expression in Patients with Classical Hodgkin Lymphoma
Authors: Priscilla Brito Silva, Juliana Monte Real, Ludmila Rodrigues Pinto Ferreira, Gustavo Henrique Esteves, Joao Garibaldi Junior, Adriana M. Damasco Penna, Fabio Nascimento Brito, Egyla Cavalcante, Otavio C. G. Baiocchi
Journal: Blood (2016)
Characteristics and outcome of patients (pts) enrolled on phase I trials: A report from the Pediatric Oncology Branch, NCI
Authors: A. Kim, E. Fox, K. Warren, S. Blaney, S. Berg, P. Adamson, M. Libucha, E. Byrley, F. Balis, B. Widemann
Journal: Journal of Clinical Oncology (2007)

9550 Background: Knowledge of the characteristics and outcomes of pts enrolled on pediatric phase I trials may aid in the design of future phase I trials and selection of pts. Methods: Pre-enrollment characteristics and treatment outcomes (toxicity, response, survival) were retrospectively analyzed from pts with refractory solid tumors enrolled in 16 phase I trials with similar eligibility criteria from 1992 to 2005. The relationship between patient characteristics and dose-limiting toxicity (DLT) was evaluated using multivariate analysis. Results: Of 262 pts (62% M, 38% F) eligible for analysis, 147 were on trials of myelosuppressive drugs (MS) and 115 were enrolled on trials of non-MS. 50 pts (19%) participated in =2 separate trials. Median (range) or (frequency) entry characteristics were: age 13.5 yrs (1–24); ECOG performance score 0 (30%), 1 (50%), 2 (19%); prior regimens 2 (0–9); prior stem cell transplant (20%); prior radiation (66%); concomitant medications 1 (0–12); and presence of metastatic disease (65%). 94% of pts were evaluable for the primary trial outcome, and 92% participated in pharmacokinetic (PK) studies. 17% of pts had grade 3 as their highest-grade toxicity. 22% of pts had grade 4 as their highest-grade toxicity, of which 91% were hematological. DLT rate was 18%. 5% of pts came off study due to toxicity, and treatment related death occurred in 0.3%. Age, prior radiation, medications, prior regimens, performance status, gender, transplant history, and drug dose expressed as a fraction of the maximum tolerated dose were included in the multivariate analysis. Only drug dose (OR 14.2, 95% CI 3.0–67.8) and prior radiation (OR 3.4, 95% CI 1.1–10.7) were statistically significantly associated with increased risk of developing DLT after adjusting for all other variables. The median number of cycles was 1 (range 0–31). Complete and partial response rate was 3%, however, 18% of pts had stable disease (received = 3 cycles). The median survival (Kaplan Meier analysis) from time of enrollment was 5 months. Conclusion: Standard phase I eligibility criteria selected a population of pts who tolerated the investigational agents well and &gt;90% were evaluable for the toxicity and PK endpoints. Prior radiation was associated with a greater risk for DLT. No significant financial relationships to disclose.
Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome
Authors: Tony Muchamuel, Monette Aujay, Mark K Bennett, Maya Dajee, Susan Demo, Christopher J Kirk, Ying Fang, Jing Jiang, Evan Lewis, Yan Lu, Guy Laidig, Francesco Parlati, Jamie Shields, Congcong m Sun, Jinfu Yang, Han-Jie Zhou
Journal: Blood (2008)
Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis
Authors: Marco Montanaro, Ambra Di Veroli, Marianna De Muro, Cristina Santoro, Massimo Breccia, Michele Cedrone, Barbara Anaclerico, Malgorzata Monika Trawinska, Raffaele Porrini, Elisabetta Abruzzese, Sabrina Leonetti Crescenzi, Nicoletta Villivà, Giuseppe Cimino, Atelda Romano, Francesca Spirito, Antonio Spadea, Agostino Tafuri, Francesco Buccisano, Roberto Ricci, Francesco Lo Coco, Giuliana Alimena, Roberto Latagliata, Alessandro Andriani
Journal: Blood (2016)
Functional Link Between Heat Shock Protein HSP90alpha and Sirtuin 1 (SIRT1) in the Pathogenesis of Diffuse Large B Cell Lymphoma
Authors: Emilia Bialopiotrowicz, Tomasz Sewastianik, Monika Noyszewska-Kania, Maciej Szydlowski, Ewa Jablonska, Patryk Gorniak, Anna Polak, Przemyslaw Kiliszek, Krzysztof Warzocha, Przemyslaw Juszczynski
Journal: Blood (2016)
RPPA-Based Protein Profiling Reveals Enhanced PI3K/AKT/mTOR Signaling in ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia Patients with Low CD200 Expression
Authors: Farzaneh Ghazavi, Valentina Serafin, Pieter Rondou, Tim Lammens, Frank Speleman, Benedetta Accordi, Barbara De Moerloose, Pieter Van Vlierberghe
Journal: Blood (2016)
Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study.
Authors: Marek Trneny, Andre Bosly, Krimo Bouabdallah, David Ma, Ofer Shpilberg, Silvia Montoto, Catherine Sebban, Hans Hagberg, Craig H Moskowitz, Norbert Schmitz, Christian Gisselbrecht
Journal: Blood (2009)
Abstract 17428: Cu Transporter ATP7A Promotes Angiogenesis by Limiting Autophagic Degradation of VEGFR2
Authors: Dipankar Ash, Seock-Won Youn, Sudhahar Varadarajan, Mustafa N Okur, John P O'Brien, Bayasgalan Surenkhuu, Tohru Fukai, Masuko Ushio-Fukai
Journal: Circulation (2017)

Background: VEGF stimulates angiogenesis through VEGFR2 in endothelial cells (ECs). Copper (Cu), an essential micronutrient, is involved in angiogenesis. Since excess Cu is toxic, intracellular Cu ...
Heterozygous Dnmt3a Mutation Induces Expansion of Hematopoietic Stem Cell Pool in a Murine Model
Authors: Takashi Higo, Junji Koya, Yoshiki Sumitomo, Takako Tsuruta-Kishino, Keisuke Kataoka, Tomohiko Sato, Mineo Kurokawa
Journal: Blood (2015)
Identification of Effective Combinations of Targeted Drugs for Hematologic Malignancies
Authors: Stephen E Kurtz, Christopher A. Eide, Andy Kaempf, Vishesh Khanna, Samantha L. Savage, Angela Rofelty, Isabel English, Hibery Ho, Motomi Mori, Elie Traer, Brian J. Druker, Jeffrey W. Tyner
Journal: Blood (2016)
Suppression of the Hemodynamic Response Function Demonstrates Altered Cerebral Vasoreactivity in Sickle Cell Disease
Authors: Melanie E. Fields, Rebecca Coalson, Liam Comiskey, Mario Ortega, Dustin K. Ragan, Allison King, Joshua Shimony, Andria L. Ford, Jin-Moo Lee, Nico Dosenbach
Journal: Blood (2016)
Haploinsufficiency of Mir-146a in High-Risk Del(5q) MDS/AML Requires an Intrachromosomal Gene Network Involving p62/TRAF6/NF-κB
Authors: Jing Fang, Andres Jerez, Christopher Rasch, Lyndsey Bolanos, Jaroslaw P. Maciejewski, Daniel T Starczynowski
Journal: Blood (2012)
Thymocyte Selection-Associated High-Mobility Group Box Protein (TOX) Induces Genomic Instability in T-Cell Acute Lymphoblastic Leukemia
Authors: Riadh Lobbardi, Jordan Pinder, Barbara Martinez-Pastor, Jessica S Blackburn, Nouran Abdelfattah, Deborah Toiber, Manon De Waard, John M. Asara, Raul Mostoslavsky, Graham Dellaire, David M. Langenau
Journal: Blood (2014)
Population-Based Analysis of Elderly Patients (&gt;70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry
Authors: Andrea Janikova, Robert Pytlik, Pavel Klener, Zbynek Bortlicek, Vit Campr, Natasa Kopalova, Katerina Benesova, Michaela Hamouzova, David Belada, Vit Prochazka, Jan Pirnos, Juraj Duras, Heidi Mocikova, Jiri Mayer, Marek Trneny
Journal: Blood (2016)
Age-Related Eye Disease and Cognitive Function
Authors: Mélanie Varin, Marie-Jeanne Kergoat, Sylvie Belleville, Gisele Li, Jacqueline Rousseau, Marie-Hélène Roy-Gagnon, Solmaz Moghadaszadeh, Ellen E. Freeman
Journal: Ophthalmology (2019)

Age-related eye disease may be associated with cognitive decline, but the scientific literature has not been consistent. Furthermore, no studies have been able to explain the relationship. Our objective was to assess whether older adults with age-related macular degeneration (AMD) or glaucoma performed worse on 6 cognitive tests compared with older adults with normal vision and, if so, to understand why.Cross-sectional analysis of hospital-based study (Maisonneuve-Rosemont Hospital Ophthalmology Clinics, Montréal, Canada).Three hundred thirty-six adults 65 years of age or older with either AMD, glaucoma, or normal vision.Cognition was measured with 6 cognitive tests administered orally. Activity levels were measured using the Victoria Longitudinal Study Activity Lifestyle Questionnaire. Visual acuity and visual field were measured. Multiple linear regression was used. Mediation was assessed using structural equation modeling.Results of the verbal fluency test (animal and letter versions), the digit span test (forward and backward versions), and the logical memory test (immediate and delayed recall).People with glaucoma showed lower scores on 3 cognitive tests than the group with normal vision: the digit span forward and backward tests (β = -0.8 [95% confidence interval (CI), -1.5 to -0.2] and β = -0.7 [95% CI, -1.3 to -0.1], respectively) and the logical memory test with immediate recall (β = -1.3 [95% CI, -2.4 to -0.2]). Activity levels statistically significantly mediated the relationship between glaucoma and the digit span forward test (P = 0.043; percentage of the total effect mediated, 17%).People with glaucoma showed lower scores on cognitive tests that may depend on verbal working memory and encoding. If confirmed in longitudinal studies, interventions should be developed that are appropriate for a visually impaired population to slow this cognitive decline.
Efficacy and Safety of Nivolumab for Non-Cutaneous Melanoma: A Retrospective Analysis from a Single Institution
Authors: Taiji Koyama, Naomi Kiyota, Yoshinori Imamura, Shiro Kimbara, Masanori Toyoda, Funakoshi Yohei, Yoshimi Fujishima, Yoko Ishikawa, Hironobu Minami
Journal: Annals of Oncology (2019)
Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells.
Authors: Karoline Veronika Gleixner, Matthias Mayerhofer, Gregor Hörmann, Karina Schuch, Sabine Cerny-Reiterer, Barbara Peter, Harald Herrmann, Winfried F. Pickl, Christian Sillaber, Peter Valent
Journal: Blood (2009)
Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation
Authors: Maria Eugenia Riveiro, Lucile Astorgues-Xerri, Charlotte Canet-jourdan, Mohamed Bekradda, Esteban Cvitkovic, Patrice Herait, Eric Raymond
Journal: Blood (2014)
Identification of Fusion Partners and Cooperating Mutations in De Novo AML with MLL Rearrangements.
Authors: Lee-Yung Shih, Der-Cherng Liang, Jen-Fen Fu, Jin-Hou Wu, Po-Nan Wang, Tung-Liang Lin, Chein-Fuang Huang, Po Dunn, Ming-Chung Kuo, Chung-Chih Tang, Tung-Huei Lin, Chang-Liang Lai
Journal: Blood (2004)
Hodgkin Lymphoma Patients Demonstrate Evidence of Systemic Perturbation of the Monocyte-Dendritic Cell Axis
Authors: Catherine Diefenbach, Bruce G. Raphael, Michael L. Grossbard, Kenneth B. Hymes, Tibor Moskovits, David Kaminetzky, Peter Martin, Jia Ruan, Megan McShea, Leonelle B'etou, Maryam Bonakdar, Cem Abidoglu, Lina Kozhaya, John P. Leonard, Derya Unutmaz
Journal: Blood (2016)
Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy
Authors: Martina Kleber, Stefanie Hieke, Bernd Koch, Gabriele Ihorst, Ralph Wäsch, Martin Schumacher, Monika Engelhardt
Journal: Blood (2012)
A Pilot Study of Epigenetic-Differentiation Therapy with Decitabine to Treat β-Thalassemia Intermedia
Authors: Nancy F Olivieri, Yogenthiran Saunthararajah, Vivekanandan Thayalasuthan, Janet Kwiatkowski, Russell E. Ware, Franz Kuypers, Hae-Young Kim, Elliott P Vichinsky
Journal: Blood (2010)
Preliminary results from fight-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies
Authors: Yasutoshi Kuboki, Masayuki Furukawa, Yasuo Takahashi, Nobumasa Mizuno, Hiroki Hara, Makoto Ueno, Tatsuya Ioka, Shunji Takahashi, Toshio Shimizu, Christine F. Lihou, Chenwei Tian, Tao Ji, Yutaka Fujiwara
Journal: Annals of Oncology (2019)
Abbreviated Regimen with 4 Cycles of Fludarabine, Cyclophosphamide and Rituximab (FCR) in Physically Fit Patients with Chronic Lymphocytic Leukemia Who Achieve Early Complete Remission with Undetectable Minimal Residual Disease: Safety and Efficacy Follow-up Results of a Single Center Experience
Authors: Carolina Pavlovsky, Isolda Fernandez, Miguel A Pavlovsky, Adriana Galeano, Federico Sackmann, Dante Intile, Astrid Pavlovsky
Journal: Blood (2015)
Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia
Authors: Esmé Waanders, Stephanie M Dobson, Xiaotu Ma, Debbie Payne-Turner, Guangchun Song, Yiping Fan, Zhaohui Gu, Ying Shao, Michael Rusch, Kelly McCastlain, Ilaria Iacobucci, Kathryn G. Roberts, Shann-Ching Chen, Pankaj Gupta, Ji Wen, Gang Wu, Jing Ma, Colin Bailey, Matthew Lear, Scott Olsen, Deanna Naeve, Geoffrey A. Neale, John Easton, Sima Jeha, Ching-Hon Pui, James R. Downing, William E. Evans, Mary V. Relling, Jun J Yang, John E. Dick, Jinghui Zhang, Charles G. Mullighan
Journal: Blood (2015)
Zap-70 and IgVH Mutation Status in Combination with p53 Functional Analysis Identifies the Response of Poor Prognosis B-CLL Patients to Conventional Cytotoxic Agents.
Authors: N. I. Folarin, R. J. Baker, V. Duke, B. C. Yogashangary, C. Vadikolia, R. G. Wickremasinghe, A. A. Casanova, M. W. Lowdell, A. Victor Hoffbrand, A. Nathwani, A. E. Virchis, A. B. Mehta, L. Foroni, K. Ganeshaguru
Journal: Blood (2004)
Steroids Are Less Effective In Treating Thrombocytopenia Caused by Immune Responses Against Platelet GPIbα: A Comparative Study Using Passive and Active ITP Models.
Authors: Elisa K. Simpson, Guangheng Zhu, Conglei Li, Lingyan Zhu, Qingshu Zeng, John W. Semple, John J. Freedman, Heyu Ni
Journal: Blood (2010)
Fibronectin Is Not the Only Important Molecule Required for Fibrinogen/VWF-Independent Platelet Aggregation: Study of Thrombosis in a New Strain of Triple Deficient Mice.
Authors: Adili Reheman, Yang Hong, Christopher M. Spring, Pingguo Chen, Denisa D. Wagner, Reinhard Fassler, John Freedman, Heyu Ni
Journal: Blood (2006)
The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators
Authors: Maria-Victoria Mateos, Norma C Gutierrez, María-Luisa Martín, Joaquín Martínez-López, Miguel-T Hernandez, Enrique M. Ocio, Laura Rosiñol, Rafael Martinez, Ana Isabel Teruel, Albert Oriol, Joan Bargay, Enrique Bengoechea, Yolanda Gonzalez, Jaime Perez de Oteyza, Mercedes Gironella, Cristina Encinas, Jesus Martin, Carmen Cabrera, Bruno Paiva, Noemi Puig, Joan Bladé, Juan José Lahuerta, Jesus San Miguel
Journal: Blood (2016)
ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)
Authors: Noopur Raje, Dan T. Vogl, Parameswaran N. Hari, Sundar Jagannath, Simon S Jones, Jeffrey G Supko, Gina Leone, Catherine Wheeler, Robert Z. Orlowski, Paul G. Richardson, Sagar Lonial
Journal: Blood (2013)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients
Authors: Robyn Scherber, Amylou Dueck, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Bjorn Andreasson, Maria L Ferarri, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegard, Ayalew Tefferi, Claire N. Harrison, Deepti Radia, Ruben A. Mesa
Journal: Blood (2010)
Integrative Genomics Approaches Identify Novel Disease-Related Genetic Aberrations in Acute Myeloid Leukemia
Authors: Anna Dolnik, Julia C Engelmann, Maren Scharfenberger-Schmeer, Frank G Rücker, Jan Krönke, Michael WM Kühn, Peter Paschka, Verena I. Gaidzik, Sabine Kayser, Richard F. Schlenk, Berit Haldemann, Stephan Wolf, Hartmut Döhner, Claudio Lottaz, Konstanze Döhner, Lars Bullinger
Journal: Blood (2011)